Medium

Step 1: The management's discussion appears optimistic as they highlight the approval and expansion of medicines for cystic fibrosis, successful clinical trials, and positive collaborations with other companies.

Step 2: They mention that in the third quarter of 2020, their net product revenues increased, while their combined R&D and SG&A expenses decreased. This indicates financial growth and effective cost management, which are positive signs.

Step 3: The increase in net product revenues, especially from the approval of TRIKAFTA and expansions into global markets, suggests a successful quarter with potential for further growth. The positive data from ongoing clinical trials also point towards a promising future.

Based on the overall positive sentiment, financial growth, and successful developments in their pipeline, the company is deemed to have a medium risk of bankruptcy. They are making significant progress in expanding their treatments and revenue streams, which should help mitigate bankruptcy risk.